{"id":"asp9831","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"}]},"_chembl":{"chemblId":"CHEMBL6068540","moleculeType":"Small molecule","molecularWeight":"353.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K delta, ASP9831 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.","oneSentence":"ASP9831 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:28.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune hemolytic anemia"}]},"trialDetails":[{"nctId":"NCT00668070","phase":"PHASE2","title":"A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04","conditions":"Non-Alcoholic Steatohepatitis","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASP9831","genericName":"ASP9831","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP9831 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of autoimmune hemolytic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}